

1. számú melléklet

Irodalomjegyzék

- [1] Scott SA. Personalizing medicine with clinical pharmacogenetics. *Genet Med.* 2011 Dec;13(12):987-95.
- [2] Voora D, Ginsburg GS. Clinical application of cardiovascular pharmacogenetics. *J Am Coll Cardiol.* 2012 Jul 3;60(1):9-20.
- [3] Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. *Trends Pharmacol Sci.* 2004 Apr;25(4):193-200.
- [4] Ventola CL. Pharmacogenomics in Clinical Practice: Reality and Expectations. *Pharmacy and Therapeutics* 2011;36(7):412-450.
- [5] Tang YM, Wo YY, Stewart J, Hawkins AL, Griffin CA, Sutter TR, et al. Isolation and characterization of the human cytochrome P450 CYP1B1 gene. *J Biol Chem* 1996;271(45):28324–30.
- [6] Li N, Zhou Y, Du L, Wei M, Chen X. Overview of Cytochrome P450 1B1 gene mutations in patients with primary congenital glaucoma. *Exp Eye Res.* 2011 Nov;93(5):572-9.
- [7] Sutter TR, Tang YM, Hayes CL, Wo YY, Jabs EW, Li X, Yin H, Cody CW, Greenlee WF, 1994. Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2. *J. Biol. Chem.* 269, 13092–13099.
- [8] Hayes CL, Spink, DC, Spink, BC, Cao JQ, Walker NJ, Sutter, TR, 1996. 17-betaestradiol hydroxylation catalyzed by human cytochrome P450 1B1. *Proc. Natl. Acad. Sci. U.S.A.* 93, 9776–9781.
- [9] Shimada T, Hayes CL, Yamazaki H, Amin S, Hecht SS, Guengerich FP, et al. Activation of chemically diverse pro carcinogens by human cytochrome P-450 1B1. *Cancer Res* 1996;56:2979–84.
- [10] Rochat B, Morsman JM, Murray GI, Figg WD, McLeod HL, 2001. Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? *J. Pharmacol. Exp. Ther.* 296, 537–541.

- [11] Sharma M, Shubert DE, Sharma M, Lewis J, McGarrigle BP, Bofinger DP, Olson JR, 2003. Biotransformation of tamoxifen in a human endometrial explant culture model. *Chem. Biol. Interact.* 146, 237–249.
- [12] Stoilov I, Akarsu AN, Alozie I, Child A, Barsoum-Homsy M, Turacli M.E, Or M, Lewis RA, Ozdemir N, Brice G, Aktan SG, Chevrette L, Coca-Prados M, Sarfarazi M, 1998. Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1. *Am. J. Hum. Genet.* 62, 573–584.
- [13] Aklillu, E., Oscarson, M., Hidestrand, M., Liedvik, B., Otter, C., Ingelman-Sundberg, M., 2002. Functional analysis of six different polymorphic *CYP1B1* enzyme variants found in an Ethiopian population. *Mol. Pharmacol.* 61, 586–594.
- [14] Klose TS, Blaisdell JA, Goldstein JA. Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. *J Biochem Mol Toxicol.* 1999;13(6):289-95.
- [15] Yasar U, Lundgren S, Eliasson E, Bennet A, Wiman B, de Faire U, Rane A. Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. *Biochem Biophys Res Commun.* 2002 Nov 22;299(1):25-8.
- [16] Goldstein JA, de Morais SM. Biochemistry and molecular biology of the human CYP2C subfamily. *Pharmacogenetics.* 1994 Dec;4(6):285-99.
- [17] Schoch GA, Yano JK, Sansen S, Dansette PM, Stout CD, Johnson EF. Determinants of cytochrome P450 2C8 substrate binding: structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid. *J Biol Chem.* 2008 Jun 20;283(25):17227-37.
- [18] Schoch GA, Yano JK, Wester MR, Griffin KJ, Stout CD, Johnson EF. Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding site. *J Biol Chem.* 2004 Mar 5;279(10):9497-503.
- [19] Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. *J Pharmacol Exp Ther.* 1994 Jul;270(1):414-23.

- [20] Totah RA, Rettie AE. Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. *Clin Pharmacol Ther.* 2005 May; 77(5):341-52.
- [21] Klose TS, Blaisdell JA, Goldstein JA. Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. *J Biochem Mol Toxicol.* 1999;13(6):289-95.
- [22] Hichiya H, Tanaka-Kagawa T, Soyama A, Jinno H, Koyano S, Katori N, Matsushima E, Uchiyama S, Tokunaga H, Kimura H, Minami N, Katoh M, Sugai K, Goto Y, Tamura T, Yamamoto N, Ohe Y, Kunitoh H, Nokihara H, Yoshida T, Minami H, Saijo N, Ando M, Ozawa S, Saito Y, Sawada J. Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population. *Drug Metab Dispos.* 2005 May;33(5):630-6.
- [23] Aquilante CL, Niemi M, Gong L, Altman RB, Klein TE. PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8. *Pharmacogenet Genomics.* 2013 Dec;23(12):721-8.
- [24] Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. *Nat Rev Cancer.* 2004 Apr;4(4):253-65.
- [25] Halder S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. *Cancer Res.* 1997 Jan 15;57(2):229-33.
- [26] Gligorov J, Lotz JP. Preclinical pharmacology of the taxanes: implications of the differences. *Oncologist.* 2004;9 Suppl 2:3-8.
- [27] Oshiro C, Marsh S, McLeod H, Carrillo MW, Klein T, Altman R. Taxane pathway. *Pharmacogenet Genomics.* 2009 Dec;19(12):979-83.
- [28] Kumar V, Singh S, Ahmed RS, Banerjee BD, Ahmed T, Pasha ST. Frequency of common CYP1B1 polymorphic variations in Delhi population of Northern India. *Environ Toxicol Pharmacol.* 2009 Nov;28(3):392-6.
- [29] Sissung TM, Danesi R, Price DK, Steinberg SM, de Wit R, Zahid M, Gaikwad N, Cavalieri E, Dahut WL, Sackett DL, Figg WD, Sparreboom A. Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel. *Mol Cancer Ther.* 2008 Jan;7(1):19-26.

- [30] Bahadur N, Leathart JB, Mutch E, Steimel-Crespi D, Dunn SA, Gilissen R, Houdt JV, Hendrickx J, Mannens G, Bohets H, Williams FM, Armstrong M, Crespi CL, Daly AK. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. *Biochem Pharmacol.* 2002 Dec 1;64(11):1579-89.
- [31] Gao Y, Liu D, Wang H, Zhu J, Chen C. Functional characterization of five CYP2C8 variants and prediction of CYP2C8 genotype-dependent effects on in vitro and in vivo drug-drug interactions. *Xenobiotica.* 2010 Jul;40(7):467-75.
- [32] Rizzo R, Spaggiari F, Indelli M, Lelli G, Baricordi OR, Rimessi P, Ferlini A. Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients. *Breast Cancer Res Treat.* 2010 Nov;124(2):593-8.
- [33] Hlavata I, Vrana D, Smerhovsky Z, Pardini B, Naccarati A, Vodicka P, Novotny J, Mohelnikova-Duchonova B, Soucek P. Association between exposure-relevant polymorphisms in CYP1B1, EPHX1, NQO1, GSTM1, GSTP1 and GSTT1 and risk of colorectal cancer in a Czech population. *Oncol Rep.* 2010 Nov;24(5):1347-53.
- [34] Pechandova K, Buzkova H, Matouskova O, Perlik F, Slanar O. Genetic polymorphisms of CYP2C8 in the Czech Republic. *Genet Test Mol Biomarkers.* 2012 Jul;16(7):812-6.
- [35] Timofeeva MN, Kropp S, Sauter W, Beckmann L, Rosenberger A, Illig T, Jäger B, Mittelstrass K, Dienemann H; LUCY-Consortium, Bartsch H, Bickeböller H, Chang-Claude JC, Risch A, Wichmann HE. CYP450 polymorphisms as risk factors for early-onset lung cancer: gender-specific differences. *Carcinogenesis.* 2009 Jul;30(7):1161-9.
- [36] Weise A, Grundler S, Zaumsegel D, Klotzek M, Gröndahl B, Forst T, Pfützner A. Development and evaluation of a rapid and reliable method for cytochrome P450 2C8 genotyping. *Clin Lab.* 2004;50(3-4):141-8.
- [37] Bethke L, Webb E, Sellick G, Rudd M, Penegar S, Withey L, Qureshi M, Houlston R. Polymorphisms in the cytochrome P450 genes CYP1A2, CYP1B1, CYP3A4, CYP3A5, CYP11A1, CYP17A1, CYP19A1 and colorectal cancer risk. *BMC Cancer.* 2007 Jul 5;7:123.
- [38] Minhas S, Setia N, Pandita S, Saxena R, Verma IC, Aggarwal S. Prevalence of CYP2C8 polymorphisms in a North Indian population. *Genet Mol Res.* 2013 Jul 8;12(3):2260-6.

- [39] Shah PP, Singh AP, Singh M, Mathur N, Mishra BN, Pant MC, Parmar D. Association of functionally important polymorphisms in cytochrome P4501B1 with lung cancer. *Mutat Res.* 2008 Aug 25;643(1-2):4-10.
- [40] Muthiah YD, Lee WL, Teh LK, Ong CE, Ismail R. Genetic polymorphism of CYP2C8 in three Malaysian ethnics: CYP2C8*2 and CYP2C8*3 are found in Malaysian Indians. *J Clin Pharm Ther.* 2005 Oct;30(5):487-90.
- [41] Liang G, Pu Y, Yin L. Rapid detection of single nucleotide polymorphisms related with lung cancer susceptibility of Chinese population. *Cancer Lett.* 2005 Jun 8;223(2):265-74.
- [42] Watanabe J, Shimada T, Gillam EM, Ikuta T, Suemasu K, Higashi Y, Gotoh O, Kawajiri K. Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer. *Pharmacogenetics.* 2000 Feb;10(1):25-33.
- [43] Nakajima M, Fujiki Y, Noda K, Ohtsuka H, Ohkuni H, Kyo S, Inoue M, Kuroiwa Y, Yokoi T. Genetic polymorphisms of CYP2C8 in Japanese population. *Drug Metab Dispos.* 2003 Jun;31(6):687-90.

2. számú melléklet

Köszönetnyilvánítás

Elsősorban Dr. Melegh Béla Professzor úrnak, a PTE KK Orvosi Genetikai Intézet vezetőjének tartozom köszönettel, aki lehetővé tette számomra, hogy az intézetükben folyó munkában részt vehessek, dolgozatomat náluk készíthessem el.

Köszönettel tartozom továbbá az Orvosi Genetikai Intézet dolgozóinak, szakmai segítségükért és türelmükért rendkívül hálás vagyok.

Kiemelt köszönet illeti konzulensemét, Szalai Renátát, aki mindvégig segítségemre volt, és akihez bármikor fordulhattam útmutatásáért és tanácsért.